[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628522":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":12,"responsibleParty":31,"collaborators":12,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":37,"acronym":12,"eligibilityCriteria":38,"healthyVolunteers":35,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":12,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":52,"overallStatus":56,"whyStopped":12,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":12},{"fullName":5,"class":6},"Guizhou Medical University","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Pharmacotherapy group","NO_INTERVENTION","For patients positive for driver gene mutations, first-line targeted therapy with or without chemotherapy is recommended according to NCCN guidelines. For patients negative for driver gene mutations, first-line immunotherapy combined with chemotherapy is recommended according to NCCN guidelines.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Radiotherapy group","EXPERIMENTAL","For patients positive for driver gene mutations, first-line targeted therapy with or without chemotherapy is recommended according to NCCN guidelines. For patients negative for driver gene mutations, first-line immunotherapy combined with chemotherapy is recommended according to NCCN guidelines. Concurrent radiotherapy for the primary tumor in combination with drug therapy.",[18],"Radiation: Three-Dimensional Radiotherapy for Primary lungTumors",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"RADIATION","Three-Dimensional Radiotherapy for Primary lungTumors","The experimental group received radical radiotherapy for the primary lung lesion in combination with first-line drug therapy recommended by the NCCN guidelines.",[14],[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Bing Lu","CONTACT","+86 13809432527","lbgymaaaa@163.com",{"type":32,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100628522","phase-iii-multicenter-randomized-controlled-clinical-study-of-three-dimensional-radiotherapy-for-primary-tumors-in-non-oligometastatic-stage-iv-non-small-cell-lung-cancer-100628522",false,"NCT07462728","Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non-Oligometastatic Stage IV Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Pathologically or cytologically confirmed stage IV NSCLC \\[9th edition, 2024\\];\n2. Non-oligometastatic disease (number of metastatic lesions \\> 5, regardless of the number of organs involved); patients with brain metastases must be conscious; the number of lung metastases must not affect lung function and allow for possible primary tumor radiotherapy;\n3. Treatment-naïve (no prior antitumor therapy); or disease control after 1-3 months of monotherapy with TKI, ALK inhibitor\u002FROS inhibitor; or disease control after 4-6 cycles of chemotherapy combined with immunotherapy;\n4. Age 18-80 years, ECOG 0-2 or KPS ≥70; no contraindications to radiotherapy, EGFR-TKI, ALK\u002FROS1 inhibitors, chemotherapy, or immunotherapy;\n5. No major organ dysfunction, or laboratory test results must meet the following criteria: Hematology , cardiac function, liver function , and renal function within normal ranges according to respective laboratory standards. Pulmonary function : FEV1 \\>50%, mild to moderate impairment of lung function.\n6. Signed informed consent before treatment (for radiotherapy, chemotherapy, immunotherapy, and targeted drug therapy);\n7. Good patient compliance with the treatment and follow-up.\n\nExclusion Criteria:\n\n1. Stage I-III NSCLC, oligometastasis (number of metastatic lesions ≤ 5), Stage IV NSCLC with malignant serous cavity effusion, or KPS ≤ 60;\n2. Patients with extensive liver metastases or lung metastases that have severely impaired liver or lung function;\n3. Patients with uncontrolled hypertension, diabetes, unstable angina, history of myocardial infarction, symptomatic congestive heart failure within the past 12 months, or uncontrolled arrhythmia; clinically diagnosed valvular heart disease; active bacterial, fungal, or viral infections; mental disorders; severe pulmonary dysfunction;\n4. Pregnant or lactating patients;\n5. Patients with a history of other active malignant tumors prior to enrollment, except for non-small cell lung cancer; excluding non-melanoma skin basal cell carcinoma, cervical carcinoma in situ, and cured early-stage prostate cancer;\n6. Patients with allergic constitution or known\u002Fsuspected allergy to any investigational drugs without alternative medications;\n7. Patients with poor compliance; Patients deemed unsuitable for participation in this trial by the investigator.","ALL","18 Years","80 Years",{"count":43,"type":44},200,"ESTIMATED","INTERVENTIONAL",[47],"NA","For patients with non-small cell lung cancer and more than five metastatic lesions (non-oligometastatic disease), does radical treatment of the primary lung lesion, in addition to pharmacotherapy, also provide benefits in terms of progression-free survival (PFS) and local control? Currently, there is limited clinical research on combining pharmacotherapy with radiotherapy for the primary lesion in non-oligometastatic patients. Therefore, this study aims to investigate whether radical radiotherapy targeting the primary lung lesion, in addition to pharmacotherapy, can improve local control and survival in non-oligometastatic patients, and whether the associated toxicities are acceptable.",[50,51],"Non Small Cell Lung Cancer Metastatic","Radiotherapy",[53,54,55],"non-oligometastatic NSCLC","radical radiotherapy of the primary lung lesion","pharmacotherapy with radiotherapy for the primary lesion","NOT_YET_RECRUITING","2026-03-08",{"date":59,"type":60},"2026-03-10","ACTUAL",{"date":62,"type":44},"2026-03-30",{"date":64,"type":44},"2027-12-30",{"name":5,"class":6}]